Targeting cuproptosis with nano material: new way to enhancing the efficacy of immunotherapy in colorectal cancer

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 3, 2024

Colorectal cancer has emerged as one of the predominant malignant tumors globally. Immunotherapy, a novel therapeutic methodology, opened up new possibilities for colorectal patients. However, its actual clinical efficacy requires further enhancement. Copper, an exceptionally crucial trace element, can influence various signaling pathways, gene expression, and biological metabolic processes in cells, thus playing critical role pathogenesis cancer. Recent studies have revealed that cuproptosis, mode cell death, holds promise to become potential target overcome resistance immunotherapy. This shows substantial combination treatment Conveying copper into tumor cells via nano-drug delivery system induce cuproptosis could offer strategy eliminating drug-resistant vastly improving immunotherapy while ultimately destroy tumors. Moreover, combining induction with other anti-tumor approaches such photothermal therapy, photodynamic chemodynamic therapy enhance effect. review aims illuminate practical significance cuproptosis-inducing nano-drugs immunotherapy, scrutinize current challenges limitations this thereby providing innovative thoughts references advancement cuproptosis-based strategies.

Language: Английский

---

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials

BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 18, 2024

PD-1 and PD-L1 inhibitors have emerged as promising therapies for advanced colorectal cancer (CRC), but their efficacy safety profiles require further evaluation. This meta-analysis aims to assess the of PD-1/PD-L1 in this patient population. A systematic review were conducted following PRISMA guidelines, with data sourced from PubMed, Embase, CENTRAL, Web Science, CNKI up August 3, 2024. Nine randomized controlled trials (RCTs) involving 1680 patients included. The primary outcomes overall survival (OS), progression-free (PFS) objective response rate (ORR), while was assessed through adverse events (AEs) grade ≥ 3 AEs. Effect sizes calculated using mean differences (MD) risk ratios (RR) 95% confidence intervals (CIs). Overall, showed that did not significantly extend OS (MD = 0.86, CI: -0.55, 2.27), they improved PFS 2.53, 0.92, 4.15). Additionally, increase ORR compared controls (RR 1.19, 0.99, 1.44). In terms safety, incidence Subgroup analysis indicated 1.24, 0.20, 2.29) 6.27, 0.56, 11.97), a significant impact on these outcomes. associated higher AEs 1.29, 1.07, 1.57), observed inhibitors. improve CRC, making them preferable option over inhibitors, which show limited severe These findings support prioritizing clinical practice group, caution is warranted due concerns. PROSPERO (CRD42024611696).

Language: Английский

---

Comparative efficacy of targeted therapies and immunotherapy in advanced non-small cell lung cancer: a systematic review

International Journal of Research in Medical Sciences, Journal Year: 2024, Volume and Issue: 12(9), P. 3384 - 3393

Published: Aug. 12, 2024

Targeted therapies and immunotherapies revolutionized advanced NSCLC treatment outcomes. exploit specific genetic mutations (e.g., EGFR, ALK, BRAF) to inhibit cancer growth while offering significant benefits in progression-free overall survival. therapy drugs for include osimertinib, gefitinib, erlotinib, alectinib, brigatinib, lorlatinib, ceritinib, dabrafenib, trametinib, crizotinib.Resistance side effects like ILD hepatotoxicity cardiovascular issues remain challenges. Immunotherapies with checkpoint inhibitors PD-1, PD-L1, CTLA-4 enhance the immune system's ability body becomes able combat cancer. Drugs pembrolizumab, nivolumab, atezolizumab have shown good efficacy but immune-related adverse a concern. Combination such as e.g., nivolumab ipilimumab can be better option which concerned because these also show promise enhancing

Language: Английский

---

Myeloid‐derived suppressor cells inhibit responses of T follicular helper cells during experimental Plasmodium yoelii infection

The FASEB Journal, Journal Year: 2024, Volume and Issue: 38(23)

Published: Dec. 4, 2024

Abstract Malaria remains a significant global public health problem. T follicular helper (Tfh) cells, subset of CD4 + have the capacity to regulate B plasma and antibody production, among other functions. Myeloid‐derived suppressor cells (MDSCs) possess strong immunosuppressive abilities can negatively various immune responses. However, role MDSCs in inhibiting Tfh‐cell responses during Plasmodium infection unclear. In this study, we investigated regulatory effect on Tfh cell‐mediated upon infection. We found that numbers increased Further mechanism study revealed MDSC‐derived Arg‐1 PD‐L1 prevented cell proliferation activation. Conversely, addition nor‐NOHA or anti‐PD‐L1 monoclonal antibodies enhanced activation indicating inhibitory was dependent PD‐1/PD‐L1. vivo depletion as well relieved symptoms infected mice improved their survival rates. These findings provide insights into further impairing humoral immunity. Our provides new strategies for malaria prevention control.

Language: Английский

---